IL117923A
(en)
*
|
1995-05-03 |
2000-06-01 |
Warner Lambert Co |
Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
|
US5620981A
(en)
*
|
1995-05-03 |
1997-04-15 |
Warner-Lambert Company |
Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
|
ES2186908T3
(es)
|
1996-07-13 |
2003-05-16 |
Glaxo Group Ltd |
Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
JP2001509805A
(ja)
*
|
1997-02-05 |
2001-07-24 |
ワーナー−ランバート・コンパニー |
細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン
|
EP1806348A3
(en)
*
|
1997-02-05 |
2008-01-02 |
Warner-Lambert Company LLC |
Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
|
US6498163B1
(en)
|
1997-02-05 |
2002-12-24 |
Warner-Lambert Company |
Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
US6150359A
(en)
*
|
1997-08-20 |
2000-11-21 |
Warner-Lambert Company |
Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
|
EP1801112A1
(en)
*
|
1998-05-26 |
2007-06-27 |
Warner-Lambert Company LLC |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
ES2310039T3
(es)
*
|
1998-05-26 |
2008-12-16 |
Warner-Lambert Company Llc |
Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
|
GB9822450D0
(en)
*
|
1998-10-14 |
1998-12-09 |
Smithkline Beecham Plc |
Medicaments
|
GB9914486D0
(en)
|
1999-06-21 |
1999-08-18 |
Smithkline Beecham Plc |
Medicaments
|
GB9917408D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
GB9917406D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
AR030044A1
(es)
*
|
2000-01-25 |
2003-08-13 |
Warner Lambert Co |
Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas
|
WO2002008224A1
(en)
|
2000-07-26 |
2002-01-31 |
Smithkline Beecham P.L.C. |
Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
|
US6518276B2
(en)
*
|
2000-08-31 |
2003-02-11 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (II)
|
AU2001293784B2
(en)
*
|
2000-08-31 |
2007-08-30 |
F. Hoffmann-La Roche Ag |
7-OXO pyridopyrimidines as inhibitors of a cellular proliferation
|
US6506749B2
(en)
|
2000-08-31 |
2003-01-14 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (I)
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
WO2002060382A2
(en)
|
2001-01-19 |
2002-08-08 |
Smithkline Beecham Corporation |
Novel compounds and uses thereof
|
GB0101577D0
(en)
|
2001-01-22 |
2001-03-07 |
Smithkline Beecham Plc |
Compounds
|
CA2434834C
(en)
*
|
2001-02-12 |
2010-09-14 |
F. Hoffmann-La Roche Ag |
6-substituted pyrido-pyrimidines
|
WO2002090360A1
(en)
*
|
2001-05-10 |
2002-11-14 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
GB0112836D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
AU2002324450A1
(en)
*
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel pyridopyrimidines and uses thereof
|
CN102295643B
(zh)
|
2002-01-22 |
2013-12-04 |
沃尼尔·朗伯有限责任公司 |
2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
|
WO2003064431A2
(en)
|
2002-01-29 |
2003-08-07 |
Glaxo Group Limited |
Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
|
US7312212B2
(en)
|
2002-01-29 |
2007-12-25 |
Glaxo Group Limited |
Aminopiperidine derivatives
|
US20050119303A1
(en)
*
|
2002-03-05 |
2005-06-02 |
Eisai Co., Ltd |
Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with an angiogenesis inhibitor
|
US7196090B2
(en)
|
2002-07-25 |
2007-03-27 |
Warner-Lambert Company |
Kinase inhibitors
|
JP4252534B2
(ja)
|
2002-08-06 |
2009-04-08 |
エフ.ホフマン−ラ ロシュ アーゲー |
p−38MAPキナーゼインヒビターとしての6−アルコキシ−ピリド−ピリミジン類
|
TW200502236A
(en)
*
|
2003-03-28 |
2005-01-16 |
Hoffmann La Roche |
Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
|
PT1685131E
(pt)
|
2003-11-13 |
2007-05-31 |
Hoffmann La Roche |
''pirido-7-pirimidin-7-onas substituídas com hidroxialquino''
|
AU2005209231B8
(en)
|
2004-01-21 |
2011-07-28 |
Emory University |
Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
|
AU2005223316A1
(en)
*
|
2004-03-15 |
2005-09-29 |
F. Hoffmann-La Roche Ag |
Novel dichloro-phenyl-pyrido [2,3-D] pyrimidine derivates, their manufacture and use as pharmaceutical agents
|
FR2873118B1
(fr)
*
|
2004-07-15 |
2007-11-23 |
Sanofi Synthelabo |
Derives de pyrido-pyrimidine, leur application en therapeutique
|
CN101014600A
(zh)
|
2004-09-21 |
2007-08-08 |
霍夫曼-拉罗奇有限公司 |
用作蛋白激酶抑制剂的6-(2-烷基-苯基)-吡啶并[2,3-d]嘧啶类
|
US20070054916A1
(en)
†
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
CA2584485C
(en)
*
|
2004-10-20 |
2013-12-31 |
Resverlogix Corp. |
Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
|
EP1833832A1
(en)
*
|
2004-12-31 |
2007-09-19 |
GPC Biotech AG |
Napthyridine compounds as rock inhibitors
|
FR2887882B1
(fr)
|
2005-07-01 |
2007-09-07 |
Sanofi Aventis Sa |
Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
|
WO2007016525A2
(en)
|
2005-07-29 |
2007-02-08 |
Resverlogix Corp. |
Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
|
ES2351939T3
(es)
|
2005-08-09 |
2011-02-14 |
Irm Llc |
Compuestos y composiciones como inhibidores de proteínas cinasas.
|
US20070082920A1
(en)
*
|
2005-10-06 |
2007-04-12 |
Yongsheng Song |
NAD+-dependent DNA ligase inhibitors
|
RU2445315C2
(ru)
*
|
2005-11-22 |
2012-03-20 |
Кудос Фармасьютиклз Лимитед |
ПРОИЗВОДНЫЕ ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
|
FR2896246B1
(fr)
|
2006-01-13 |
2008-08-15 |
Sanofi Aventis Sa |
Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
|
CA2636981A1
(en)
|
2006-01-31 |
2007-08-09 |
F. Hoffmann-La Roche Ag |
7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
|
CA2663401C
(en)
|
2006-09-15 |
2011-07-12 |
Pfizer Products Inc. |
Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
|
CA2668731A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Tobias Gabriel |
Kinase inhibitors and methods for using the same
|
FR2910813B1
(fr)
|
2006-12-28 |
2009-02-06 |
Sanofi Aventis Sa |
Nouvelle utilisation therapeutique pour le traitement des leucemies
|
DK2118074T3
(en)
|
2007-02-01 |
2014-03-10 |
Resverlogix Corp |
Compounds for the prevention and treatment of cardiovascular diseases
|
WO2008104473A2
(en)
*
|
2007-02-28 |
2008-09-04 |
F. Hoffmann-La Roche Ag |
Pyrazolopyriidine derivatives and their use as kinase inhibitors
|
WO2009100176A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
NZ594332A
(en)
|
2009-01-08 |
2013-09-27 |
Resverlogix Corp |
Compounds for the prevention and treatment of cardiovascular disease
|
NZ755378A
(en)
|
2009-03-18 |
2022-07-29 |
Resverlogix Corp |
Novel quinazolinones and related compounds for use as anti-inflammatory agents
|
US9757368B2
(en)
|
2009-04-22 |
2017-09-12 |
Resverlogix Corp. |
Anti-inflammatory agents
|
ES2347630B1
(es)
*
|
2009-04-29 |
2011-09-08 |
Universitat Ramon Llull |
Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
|
EP2332939A1
(en)
*
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
GB0922589D0
(en)
*
|
2009-12-23 |
2010-02-10 |
Almac Discovery Ltd |
Pharmaceutical compounds
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
PT2773354T
(pt)
|
2011-11-01 |
2019-07-17 |
Resverlogix Corp |
Formulações orais de libertação imediata para quinazolinonas substituídas
|
EA036592B1
(ru)
|
2012-06-13 |
2020-11-26 |
Инсайт Холдингс Корпорейшн |
Замещенные трициклические соединения как ингибиторы fgfr
|
LT2872491T
(lt)
*
|
2012-07-11 |
2021-08-25 |
Blueprint Medicines Corporation |
Fibroblasto augimo faktoriaus receptoriaus inhibitoriai
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
CA2895905A1
(en)
|
2012-12-21 |
2014-06-26 |
Zenith Epigenetics Corp. |
Novel heterocyclic compounds as bromodomain inhibitors
|
TWI647220B
(zh)
|
2013-03-15 |
2019-01-11 |
美商西建卡爾有限責任公司 |
雜芳基化合物及其用途
|
MY181020A
(en)
|
2013-03-15 |
2020-12-16 |
Sanofi Sa |
Heteroaryl compounds and uses thereof
|
AU2014228746B2
(en)
*
|
2013-03-15 |
2018-08-30 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
WO2014172644A2
(en)
|
2013-04-19 |
2014-10-23 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
JP6458023B2
(ja)
|
2013-10-25 |
2019-01-23 |
ブループリント メディシンズ コーポレイション |
繊維芽細胞成長因子受容体の阻害剤
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
ES2895769T3
(es)
|
2015-02-20 |
2022-02-22 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores de FGFR
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
CA2977308A1
(en)
|
2015-03-13 |
2016-09-22 |
Resverlogix Corp. |
Compositions and therapeutic methods for the treatment of complement-associated diseases
|
AU2016248056B2
(en)
*
|
2015-04-14 |
2020-07-23 |
Eisai R&D Management Co., Ltd. |
Crystalline FGFR4 inhibitor compound and uses thereof
|
CN104774183B
(zh)
*
|
2015-04-24 |
2017-10-13 |
合肥新诺华生物科技有限公司 |
一种甲酰基瑞舒伐汀钙中间体的制备方法
|
WO2018023081A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Achaogen, Inc. |
6-phenylpyrido[2,3-d]pyrimidine compounds as antibacterial agents
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
MX2020011189A
(es)
|
2018-04-23 |
2020-11-13 |
Univ Kyoto |
Inhibidor de crecimiento.
|
US11174257B2
(en)
|
2018-05-04 |
2021-11-16 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
CA3099287A1
(en)
|
2018-05-04 |
2019-11-07 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
EP4037683A1
(en)
*
|
2019-10-01 |
2022-08-10 |
Goldfinch Bio, Inc. |
Substituted 1, 6-naphthyridine inhibitors of cdk5
|
CR20220169A
(es)
|
2019-10-14 |
2022-10-27 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores de fgfr
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|